JP2015516985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516985A5 JP2015516985A5 JP2015509208A JP2015509208A JP2015516985A5 JP 2015516985 A5 JP2015516985 A5 JP 2015516985A5 JP 2015509208 A JP2015509208 A JP 2015509208A JP 2015509208 A JP2015509208 A JP 2015509208A JP 2015516985 A5 JP2015516985 A5 JP 2015516985A5
- Authority
- JP
- Japan
- Prior art keywords
- gcc
- antibody molecule
- cancer
- item
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 80
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 51
- 239000012472 biological sample Substances 0.000 claims description 35
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 27
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 26
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 206010039491 Sarcoma Diseases 0.000 claims description 18
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- 239000011541 reaction mixture Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
- 201000005202 lung cancer Diseases 0.000 claims description 13
- 238000002626 targeted therapy Methods 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 239000002254 cytotoxic agent Substances 0.000 claims description 10
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000009956 adenocarcinoma Diseases 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 238000001574 biopsy Methods 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 7
- 201000002314 small intestine cancer Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000003364 immunohistochemistry Methods 0.000 claims description 5
- 208000037841 lung tumor Diseases 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000011002 quantification Methods 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 claims description 2
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 claims description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 101710128063 Carbohydrate oxidase Proteins 0.000 claims description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims description 2
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 2
- 102100022624 Glucoamylase Human genes 0.000 claims description 2
- 108060001084 Luciferase Proteins 0.000 claims description 2
- 239000005089 Luciferase Substances 0.000 claims description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 230000002055 immunohistochemical effect Effects 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 239000012217 radiopharmaceutical Substances 0.000 claims description 2
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 2
- 208000014680 small intestine neoplasm Diseases 0.000 claims description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 claims description 2
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 6
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 6
- 108010044540 auristatin Proteins 0.000 description 6
- 108010093470 monomethyl auristatin E Proteins 0.000 description 6
- 108010059074 monomethylauristatin F Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639376P | 2012-04-27 | 2012-04-27 | |
| US61/639,376 | 2012-04-27 | ||
| PCT/US2013/038542 WO2013163633A1 (en) | 2012-04-27 | 2013-04-27 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017087084A Division JP6517267B2 (ja) | 2012-04-27 | 2017-04-26 | 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516985A JP2015516985A (ja) | 2015-06-18 |
| JP2015516985A5 true JP2015516985A5 (enExample) | 2016-06-16 |
| JP6472746B2 JP6472746B2 (ja) | 2019-02-20 |
Family
ID=49477498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509208A Active JP6472746B2 (ja) | 2012-04-27 | 2013-04-27 | 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 |
| JP2017087084A Active JP6517267B2 (ja) | 2012-04-27 | 2017-04-26 | 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017087084A Active JP6517267B2 (ja) | 2012-04-27 | 2017-04-26 | 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 |
Country Status (41)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20196956B (en) | 2009-10-23 | 2019-03-25 | British Columbia Amgen | Anti-gcc antibody molecules and related compositions and methods |
| CA2928043A1 (en) * | 2013-10-21 | 2015-04-30 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| US10351897B2 (en) | 2014-02-14 | 2019-07-16 | Bioventures, Llc | Acetaminophen adducts and methods of use thereof |
| AU2015358373B2 (en) | 2014-12-03 | 2021-05-27 | Arkansas Children's Research Institute | Anti-acetaminophen antibodies and acetaminophen protein adducts |
| US11090383B2 (en) | 2015-10-01 | 2021-08-17 | Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| EP3551745A4 (en) * | 2016-12-12 | 2020-07-15 | Xcella Biosciences, Inc. | SCREENING METHODS AND SYSTEMS USING MICROCAPILLARY NETWORKS |
| KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
| US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| JP7197584B2 (ja) * | 2017-12-06 | 2022-12-27 | ベンタナ メディカル システムズ， インコーポレイテッド | デジタル病理学分析結果の格納および読み出し方法 |
| JP2021535180A (ja) * | 2018-09-05 | 2021-12-16 | ユニベルシテイト ファン アムステルダム | パーキンソン病の処置の為のｐｄｅ１１又はｐｄｅ２阻害剤の使用 |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| TW202210513A (zh) * | 2020-06-02 | 2022-03-16 | 日商帝人製藥股份有限公司 | 抗ｉｇｆ－１受體人源化抗體 |
| BR112023011658A2 (pt) * | 2020-12-17 | 2023-10-17 | Parasol Biotech Ltd | Anticorpo de domínio único anti-gucy2c (sdab), receptor de antígeno quimérico (car), ácido nucleico isolado, vetor, célula efetora imune manipulada, composição farmacêutica e método de tratamento de uma doença ou distúrbio em um sujeito |
| IL307367A (en) * | 2021-04-07 | 2023-11-01 | Lg Chemical Ltd | GUCY2C binding polypeptide and uses thereof |
| JP2025533779A (ja) * | 2022-09-28 | 2025-10-09 | レジェンド バイオテック アイルランド リミテッド | Ｇｃｃを標的とする抗体及びキメラ抗原受容体並びにそれらの使用方法 |
| KR20250099224A (ko) | 2022-11-01 | 2025-07-01 | 하이델베르크 파마 리서치 게엠베하 | 항-gucy2c 항체 및 이의 용도 |
| CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| WO2025061149A1 (zh) * | 2023-09-21 | 2025-03-27 | 南京传奇生物科技有限公司 | 抗gcc抗体、嵌合抗原受体及其用途 |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
| ES2216004T3 (es) | 1993-10-26 | 2004-10-16 | Thomas Jefferson University | Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas. |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| CA2254082C (en) | 1996-05-03 | 2012-09-11 | Thomas Jefferson University | Metastatic colorectal cancer vaccine |
| WO1997042506A1 (en) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| JP2003535580A (ja) | 2000-03-27 | 2003-12-02 | トーマス ジェファーソン ユニバーシティ | 高特異性マーカー検出 |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| IL157041A0 (en) | 2001-01-26 | 2004-02-08 | Inhibitex Inc | Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections |
| ES2539132T3 (es) | 2001-03-29 | 2015-06-26 | Synergy Pharmaceuticals, Inc. | Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis |
| JP4303475B2 (ja) | 2001-04-13 | 2009-07-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｖｌａ−１に対する抗体 |
| ES2289174T3 (es) | 2001-12-28 | 2008-02-01 | Amgen Fremont Inc. | Anticuerpos contra el antigeno muc-18. |
| US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1599165A4 (en) | 2003-02-10 | 2010-09-08 | Univ Jefferson | THE USE OF GCC LIGANDS |
| EP2357237A1 (en) | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
| US8563682B2 (en) | 2004-06-25 | 2013-10-22 | Thomas Jefferson University | Guanylylcyclase C ligands |
| SI1838733T1 (sl) | 2004-12-21 | 2011-12-30 | Medimmune Ltd | Protitelesa usmerjena na angiopoietin-2 in njih uporaba |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2009023457A1 (en) * | 2007-08-10 | 2009-02-19 | Centocor, Inc. | Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| ES2517872T3 (es) | 2007-08-10 | 2014-11-04 | Regeneron Pharmaceuticals, Inc. | Anticuerpos humanos de alta afinidad para el factor de crecimiento nervioso humano |
| EP2220492B1 (en) * | 2007-11-30 | 2011-08-31 | Genentech, Inc. | Vegf polymorphisms and anti-angiogenesis therapy |
| CA2760050A1 (en) | 2008-05-13 | 2009-11-19 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
| EP2296685B1 (en) | 2008-06-04 | 2015-09-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| EP2370098A4 (en) | 2008-12-03 | 2013-07-17 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| US9364477B2 (en) * | 2009-02-12 | 2016-06-14 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| CA2752668A1 (en) | 2009-02-25 | 2010-09-02 | Diagnocure Inc. | Method for detecting metastasis of gi cancer |
| WO2010104035A1 (ja) * | 2009-03-12 | 2010-09-16 | 学校法人近畿大学 | 非小細胞肺癌に対する化学療法の治療効果予測方法 |
| WO2010147684A1 (en) | 2009-06-15 | 2010-12-23 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
| JP5955771B2 (ja) | 2009-10-22 | 2016-07-20 | トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法 |
| GEP20196956B (en) * | 2009-10-23 | 2019-03-25 | British Columbia Amgen | Anti-gcc antibody molecules and related compositions and methods |
| WO2011150454A1 (en) * | 2010-06-01 | 2011-12-08 | Monash University | ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET |
| CA2806447A1 (en) * | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Neuropilin as a biomarker for bevacizumab combination therapies |
| WO2013016662A1 (en) | 2011-07-28 | 2013-01-31 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| WO2014134311A1 (en) * | 2013-02-28 | 2014-09-04 | Millennium Pharmaceuticals, Inc. | Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer |
-
2013
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko not_active Expired - Fee Related
- 2013-04-27 CA CA2871614A patent/CA2871614C/en active Active
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/me unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en not_active IP Right Cessation
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 SM SM20190536T patent/SMT201900536T1/it unknown
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/en not_active Ceased
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en not_active Ceased
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/en active Active
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
-
2014
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-24 PH PH12014502399A patent/PH12014502399B1/en unknown
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja active Active
-
2019
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516985A5 (enExample) | ||
| JP2025121970A (ja) | 癌の処置 | |
| JP6666905B2 (ja) | Ｐｄ−ｌ１抗体及びその使用 | |
| JP5770219B2 (ja) | Ｌｏｘおよびｌｏｘｌ２阻害剤ならびにこれらの使用 | |
| JP2010518847A5 (enExample) | ||
| JP2016503295A5 (enExample) | ||
| JP7022191B2 (ja) | 前立腺がんの分析のための組成物及び方法 | |
| CN103476428B (zh) | 用于诊断上皮源性癌症的血液标志物及其单克隆抗体 | |
| JP2015533788A5 (enExample) | ||
| CA2871614A1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
| JP2015172045A5 (enExample) | ||
| KR20230145514A (ko) | 엽산 수용체 1의 검출을 위한 항체 및 분석 | |
| ES2848857T3 (es) | Anticuerpos monoclonales humanos contra EphA4 y su uso | |
| JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
| JP2020510409A5 (enExample) | ||
| WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal | |
| BR112020010856A2 (pt) | Uso de conjugado de anticorpo anti-her2-fármaco no tratamento de carcinoma urotelial | |
| Kim et al. | Molecular imaging of colorectal tumors by targeting colon cancer secreted protein-2 (CCSP-2) | |
| JP2010535506A5 (enExample) | ||
| CN104977416A (zh) | 用于预测抗c-met抗体的效果的生物标志物 | |
| KR102058150B1 (ko) | 담도 세포에서 메티오닐-티알엔에이 합성효소를 이용한 담도암 진단 방법 | |
| KR101439856B1 (ko) | 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 | |
| WO2018135653A1 (ja) | 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出 | |
| CN115210256A (zh) | 用于前列腺癌诊断的新方法和化合物 | |
| US11340219B2 (en) | Anti-pY1235-MET immunological binding reagent |